Can slim people use Mounjaro for weight loss?

You're not quite overweight by the charts, but you're not entirely comfortable either

This is one of the most common situations our prescribers encounter. Someone has spent months trying to lose a modest amount of weight through diet and exercise, they've read about tirzepatide's clinical trial results, and they want to know whether the medicine could help them too. It's a reasonable question, and it deserves a straight answer rather than a dismissive one.

The UK licence for Mounjaro draws the line at a BMI of 27, provided at least one weight-related condition is present. That condition could be prediabetes, high cholesterol, high blood pressure, obstructive sleep apnoea, or osteoarthritis, among others. If your BMI is 28 and you have a GP-confirmed diagnosis of hypertension, you fall within the licensed indication. If your BMI is 28 and your health markers are all normal, you do not. The distinction matters because the clinical evidence supporting the medicine was gathered in populations meeting those criteria. You can read more about the science behind tirzepatide's mechanism and trial programme on our tirzepatide overview page.

It is also worth knowing that for people from South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean backgrounds, UK guidance applies a threshold 2.5 kg/m² lower than the headline figures, so the qualifying BMI for a weight-related condition is 24.5 rather than 27. This reflects well-established differences in cardiometabolic risk at lower BMI readings across these groups.

Why Mounjaro isn't prescribed for purely cosmetic weight loss

The MHRA has been direct on this point: GLP-1 medicines, including tirzepatide, are not assessed or approved for quick or cosmetic weight loss. That statement comes from the government's own public guidance on GLP-1 medicines and is worth understanding rather than dismissing.

The clinical trials that earned Mounjaro its licence enrolled adults with obesity or overweight accompanied by serious health conditions. SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with a BMI of 30 or above (or 27 or above with a qualifying condition) and found average weight reductions of around 20–21% at the highest dose over 72 weeks. These results reflect what the medicine does in the population it was designed for. Applying those numbers to someone at a healthy weight is speculative, and the safety and benefit balance at lower BMI levels simply has not been studied.

Prescribers who offer Mounjaro to people outside the licensed criteria are acting outside the evidence base and, depending on circumstances, outside their professional obligations. If you have come across sellers offering tirzepatide without a clinical assessment, that is a red flag worth taking seriously, the MHRA has warned repeatedly about counterfeit and illegally supplied weight-loss pens circulating online.

What 'slim' actually means when it comes to Mounjaro eligibility

BMI is an imperfect measure. A person with a BMI of 26 might carry significant visceral fat, have prediabetes, and be at real metabolic risk. Another person at the same number might have none of those concerns. This is exactly why the licence isn't just a BMI cut-off, it's a BMI cut-off plus a clinical picture.

If you feel your weight is affecting your health but your BMI doesn't comfortably clear the threshold, the most useful step is to understand your qualifying conditions, if any exist. Our dedicated page on Mounjaro for slimmer patients sets out what the threshold actually means for people in this situation. The NHS medicines page on tirzepatide sets out who the treatment is for in plain terms. The Mounjaro page on this site covers the full eligibility picture alongside what the treatment involves.

There is also a broader point about what treatment is actually for. The medicine reduces appetite, slows gastric emptying, and alters how the body handles blood sugar. In people carrying enough weight to meet the licence, that translates into meaningful health improvements alongside weight loss. In someone already at a healthy weight, the risk-benefit calculation looks very different, and reading about people on Mounjaro and their varied health profiles can help illustrate why the eligibility criteria exist in the first place. Our clinical team applies that kind of thinking to every consultation, it isn't a tick-box exercise.

If Mounjaro isn't appropriate right now, what options exist?

People who don't currently meet the Mounjaro eligibility criteria aren't without options. For those who are close to the 27 BMI threshold and have undiagnosed or unmanaged health conditions, a conversation with a GP could establish whether a qualifying condition exists. Conditions like hypertension or prediabetes are often discovered during routine checks rather than actively presenting as symptoms.

For anyone whose weight and health profile genuinely falls outside the licensed range for injectable or oral GLP-1 medicines, NHS-backed lifestyle support remains the evidence-based starting point. The NHS Better Health programme and NHS Live Well healthy weight guidance cover diet, activity, and behaviour-change support that work for the full population.

For those who do meet the licensed criteria and want to understand what a private prescription route looks like, our treatment page explains the consultation process. You can also look at how many people are currently taking Mounjaro and how others in a similar situation have approached the decision. And if you're curious about how often the medicine doesn't produce the expected results, this page on when Mounjaro doesn't work is worth reading before you start. Check your eligibility through a free consultation if you think you may qualify, our prescribers will give you a clear, honest answer either way.